- Compugen is an early-stage biotechnology company developing cancer immunotherapies from predictive computational discovery platforms.
- Compugen has an early-stage pipeline of three computationally-discovered therapeutic programs (COM701, COM902, and BAY 1905254) targeting immune checkpoints across various combination and monotherapy trials for various cancer-indications.
- Compugen is financially stable with cash at $124M as of FYE 2020 (~3-years of cash burn) and revenues projected to reach $45M by 2024 growing to $1.26B by 2029.
- Compugen has various short-term catalysts the soonest being updated data in Q2 2021 from Phase 1 trials for COM701 - monotherapy and COM701 + Opdivo® - combination therapy.
- In summary, the author projects Compugen Ltd. as a "buy" at a 4-6 year price target of $40.5/share (+334% upside).
For further details see:
Compugen: Serious Partnerships, Tremendous Potential, But Several Years To Wait